Gastrointestinal Cancer News

Fruquintinib plus paclitaxel significantly improved PFS in patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to results from a phase 3 trial presented during an ASCO Plenary Series session.

The FDA granted 510(k) clearance to Cyted’s EndoSign, a non-endoscopic capsule sponge device intended to gather pan-esophageal samples for early detection of esophageal cancer as well as other conditions, according to a company release.

Researchers estimated the global lifetime risk for developing gastrointestinal cancer in 2020 was one in 12 people, while one in 16 people will die, with colorectal cancer presenting the highest risk compared with other GI cancers.

Incidence of new portal vein thrombosis was higher after transarterial chemoembolization for hepatocellular carcinoma compared with microwave or radiofrequency ablation, although researchers reported no clinically significant sequalae.

In this video, Rachna T. Shroff, MD, MS, of University of Arizona Cancer Center, discusses highlights from ASCO Gastrointestinal Cancers Symposium.

A regimen of pembrolizumab plus chemotherapy given before and after surgery induced a pathologic objective response in approximately 60% of patients with advanced gastric cancers, phase 2 study results published in JAMA Oncology showed.

Patients who underwent cancer surgery had an increased risk for venous thromboembolism for up to 1 year after the procedure, results from a retrospective study published in JAMA Network Open showed.

As the broader health care field strives to identify and address health care disparities, a commentary published in The Lancet Oncology underscored the importance of eliminating ableism from cancer care.

The proportion of individuals with newly diagnosed cancer who lacked insurance in the U.S. declined significantly from 2010 to 2019, according to data published in Health Affairs Scholar.

Cancer research and advocacy funding disproportionately skewed toward certain subtypes, leaving many cancers with high mortality rates and those affecting Black patients underfunded, study results in JCO Oncology Practice showed.